Revenue: As of FY2025 Q3, the actual value is USD 2.523 M, beating the estimate of USD 1.76 M.EPS: As of FY2025 Q3, the actual value is USD -0.17.EBIT: As of FY2025 Q3, the actual value is USD -13.05 M.<h3>Segment Revenue</h3><ul><li>Total Revenue: $2,523,000 for the three months ended September 30, 2025, compared to $1,810,000 for the same period in 2024, representing a 39.4% increase.</li><li>Total Revenue: $5,830,000 for the nine months ended September 30, 2025, compared to $5,060,000 for the same period in 2024, representing a 15.2% increase.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: $864,000 for the three months ended September 30, 2025, compared to $414,000 for the same period in 2024, representing a 108.7% increase.</li><li>Gross Profit: $1,469,000 for the nine months ended September 30, 2025, compared to $1,037,000 for the same period in 2024, representing a 41.7% increase.</li><li>Net Loss: -$12,708,000 for the three months ended September 30, 2025, compared to -$7,890,000 for the same period in 2024.</li><li>Net Loss: -$37,025,000 for the nine months ended September 30, 2025, compared to -$22,831,000 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: -$25,758,000 for the nine months ended September 30, 2025, compared to -$15,118,000 for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: $14,575,000 for the nine months ended September 30, 2025, compared to $4,399,000 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $55,569,000 for the nine months ended September 30, 2025, compared to $16,889,000 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Gross Margin: Increased to 34.2% during the three months ended September 30, 2025, from 22.9% during the same period in 2024.</li><li>Gross Margin: Increased to 25.2% for the nine months ended September 30, 2025, from 20.5% for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: InspireMD, Inc. plans to continue the commercialization of its products and raise capital through the sale of additional equity securities, debt, or capital inflows from strategic partnerships and exercise of warrants.</li><li>Non-Core Business: The company is developing a new transcarotid artery revascularization (TCAR) system, SwitchGuard™ neuroprotection system, for transcarotid access and neuro protection, and intends to explore new indications for CGuard to leverage the advantages of stent design and mesh protection.</li><li>Priority: The company aims to establish the CGuard Carotid Stent System as a viable alternative to vascular surgery, estimating the addressable market to be approximately $1.3 billion, with potential growth to $9.3 billion.</li></ul>

InspireMD | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 2.523 M